Enterome
Delivering the promise of immunotherapy
France
49 employees
Series Unknown
Total: $175.80M
Biopharma, Biotechnology +2
General Information
Get notified when Enterome moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Enterome
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biopharma
About Enterome
Taxonomy: Immunotherapy, Biopharmaceuticals, Drug Discovery, OncoMimics, Cancer Treatment, Immunomodulatory Drugs, Phase 2 Clinical Trials, Tumor Associated Antigens, CD8 T cell Response, Glioblastoma, Adrenal Malignancies, Colorectal Cancer, Clinical-stage Biotech, Immunotherapies, Metagenomics
Services & Products
Target Customers
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | 1 | •••• •••• | 30 Oct 2023 |
| Series F | •••••• | - | 14 Jul 2022 | |
| Series E | •••••• | 6 |
|
25 Jun 2020 |
| Debt Financing | •••••• | 8 |
|
04 Jan 2018 |
| Series D | •••••• | 7 |
|
01 Jan 2017 |
Enterome Alternatives & Competitors
Pioneering new horizons in ovarian cancer treatment with a focus on autophagy through our innovative...
Clinical-stage drug discovery and development of advanced novel medicines for cancer and other sever...
Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...
FAQ About Enterome
Don't just browse. Track.
Signal Tracker monitors Enterome and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.